Acknowledgements
melanoma, Patricia, P., W.
OVARIAN CANCER, MELANOMA
The authors thank the funder and all the participants of the trial. The authors also thank the DSMB (Patricia Valery, Chair; Kerrie Sanders, IeWen Sim) for their role. The PIQ-6 tool was used under licence from QualityMetric. Thanks to them for the tool.The D-Health Trial was funded by National Health and Medical Research Council (NHMRC) of Australia. DCW and PMW are funded by research fellowships from the NHMRC.The author contributions are as follows: Study concept and design: R. N., A. R., M. W., C. B., B. D. R., D. M., B. A., P. E., D. E., G. H., M. K., R. O., J. V., A. V., P. W., D. W. Data management: R. N., M. W., A. R. Statistical analysis: A. R., R. N., M. W. Review of statistical analysis plan: R. N., A. R., M. W., C. B., B. D. R., D. M., B. A., P. E., D. E., G. H., M. K., R. O., J. V., A. V., P. W., D. W. Manuscript preparation: A. R., R. N. Manuscript review: R. N., A. R., M. W., C. B., B. D. R., D. M., B. A., P. E., D. E., G. H., M. K., R. O., J. V., A. V., P. W., D. W.The authors report no conflict of interest. PMW has funding from AstraZeneca for an unrelated study of ovarian cancer. PRE reports grants and honoraria from Amgen, honoraria from Sanofi, grants from Novartis, grants from Eli-Lilly and grants from Alexion. All other authors declare no competing interests. DCW has received speaker fees from Pierre Fabre for unrelated work on melanoma.